Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 30pembrolizumab 24Magnetic Resonance Spectroscopy 24Specimen Handling 20Cetuximab 18Nivolumab 15Carboplatin 14Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Radiotherapy, Intensity-Modulated 11Radiotherapy 10Radiation 9Paclitaxel 9Docetaxel 8Biopsy 8Immunoglobulin G 7Disulfides 7Surveys and Questionnaires 6Ipilimumab 6atezolizumab 5Fluorouracil 5toripalimab 4dostarlimab 4cemiplimab 4cabozantinib 4Taxes 4Gemcitabine 4CTLA-4 Antigen 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Maintenance × Head & Neck × 30 days × Clear all
NCT06277050 2026-05-15

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Jiangxi Provincial Cancer Hospital

Phase 3 Recruiting
264 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡